Chris Stayer
6.3K posts
BREAKING: #SCOTUS grants stay of decision blocking Alabama from using its 2023 maps. More litigation to come, but it appears Alabama will be able to use the 2023 maps for this election cycle - likely giving GOP +1 advantage for House seat.
I’ve got sources too: Lindsey Graham voted with Biden more than any other Republican. 54% in 2023. I don’t care what it was our senator should never vote 54% with a geriatric liberal like Biden. Unlike you mines an actual real source. abcnews.com/538/member-con…
🚨 BREAKING: FLORIDA LEGISLATURE FORMALLY APPROVES ABOLISHING PROPERTY TAXES for most primary homeowners statewide Both chambers RESOUNDINGLY pass Gov. Ron DeSantis’ proposal, SENDING IT TO VOTERS for approval this November LET’S GO!!! ☀️👏🏻 Needs 60% of voters this fall. Florida is MAKING HISTORY! The homestead exemption will surge up to $250K to start, and a schedule will set its elimination in the future However, MOST homeowners will already get effective 0 taxes under the proposal. DO IT NATIONWIDE!
🚨 BREAKING: MAJOR clashes underway between NJ police and anti-ICE rioters in Newark SUPER physical fights WE NEED NATIONAL GUARD!
The U.S. government published an official report documenting what happened to J6 defendants in the DC jail. Feces on the walls. Black mold. No attorneys. No family contact. Solitary confinement for 200 days — for people who hadn’t been convicted of anything. This isn’t opinion. This is a congressional eyewitness report on govinfo.gov/content/pkg/GO…
🚨 BOMBSHELL ALERT: TREASON UNRAVELING IN REAL TIME?! 🚨 WELL… ISN’T THIS THE MOTHER OF ALL COINCIDENCES?! What if the URANIUM Hillary Clinton sold to Russia — while she was Secretary of State — somehow ended up in Iran’s nuclear stockpile… right after Obama shipped them plane-loads of cash?! The enriched uranium Iran just surrendered? If forensic tests MATCH it to the Uranium One batch… GAME OVER. Hillary. Obama. JAIL. TREASON. HISTORY BOOKS. No more hiding behind “controversy-free” fairy tales. Obama’s legacy is cracking wide open — and the American people are finally waking up to the greatest scandal of our lifetime. This isn’t a conspiracy. This is karma catching up. Trump was right all along. Who else is ready for the TRUTH to drop like a nuke?! 🔥🇺🇸 #UraniumOne #LockThemUp #ObamaGate #MAGA
My dilemma for June 9 in SC: I despise Lindsey Graham, & have for yrs, but his opponent isn't glowing either. W/Lindsey I get a flip-flopping, turncoat RINO (who Pres Trump endorsed.) The other guy? Has an iffy past and potentially questionable character.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try. @twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
